Jiménez Natalia, Puig Margarita M, Pol Olga
Laboratori de Neurofarmacologia Molecular, Institut de Recerca, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Edifici C-Z, 08193 Barcelona, Spain.
J Pharmacol Exp Ther. 2006 Jan;316(1):261-70. doi: 10.1124/jpet.105.091991. Epub 2005 Sep 23.
The study evaluates the effects of kappa- (KOR), delta- (DOR), and mu-opioid receptor (MOR) agonists on the inhibition of plasma extravasation during acute and chronic intestinal inflammation in mice. The antiexudative effects of KOR and DOR agonists in animals treated with nitric oxide synthase (NOS) inhibitors and their protein levels in the gut (whole jejunum and mucosa) and spinal cord of mice with chronic intestinal inflammation were also measured. Inflammation was induced by the intragastric administration of one (acute) or two (chronic) doses of croton oil. Plasma extravasation was measured using Evans blue and protein levels by Western blot and immunoprecipitation. Plasma extravasation was significantly increased 2.7 times during chronic inflammation. The potency of the KOR agonist trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolydinyl)cyclohexyl]-benzeneazetamine (U50,488H) inhibiting plasma extravasation was enhanced 26.3 times during chronic compared with acute inflammation. [d-Pen(2),d-Pen(5)]-Enkephalin (DPDPE) (a DOR agonist) was also 11.8 times more potent during chronic inflammation, whereas the antiexudative effects of fentanyl (a MOR agonist) were not significantly altered. Receptor-specific antagonists reversed the effects. Protein levels of KOR and DOR in the whole jejunum and mucosa were significantly increased after chronic inflammation. Treatment with NOS inhibitors N(omega)-nitro-l-arginine methyl ester or l-N(6)-(1-iminoethyl)-lysine hydrochloride diminished plasma extravasation and inhibited the increased antiexudative effects of U50,488H and DPDPE during chronic intestinal inflammation. The data show that the enhanced antiexudative effects of KOR and DOR agonists could be related to an increased expression of KOR and DOR in the gut and that the release of nitric oxide may play a role augmenting the effects of opioids during chronic inflammation.
该研究评估了κ-(KOR)、δ-(DOR)和μ-阿片受体(MOR)激动剂对小鼠急性和慢性肠道炎症期间血浆外渗抑制作用的影响。还测量了KOR和DOR激动剂在接受一氧化氮合酶(NOS)抑制剂治疗的动物中的抗渗出作用,以及它们在慢性肠道炎症小鼠的肠道(整个空肠和黏膜)和脊髓中的蛋白水平。通过胃内给予一剂(急性)或两剂(慢性)巴豆油诱导炎症。使用伊文思蓝测量血浆外渗,通过蛋白质印迹法和免疫沉淀法测量蛋白水平。慢性炎症期间血浆外渗显著增加2.7倍。与急性炎症相比,KOR激动剂反式-3,4-二氯-N-甲基-N-[2-(1-吡咯烷基)环己基]-苯乙胺(U50,488H)抑制血浆外渗的效力在慢性炎症期间增强了26.3倍。[d- Pen(2),d- Pen(5)]-脑啡肽(DPDPE)(一种DOR激动剂)在慢性炎症期间的效力也高11.8倍,而芬太尼(一种MOR激动剂)的抗渗出作用没有显著改变。受体特异性拮抗剂逆转了这些作用。慢性炎症后,整个空肠和黏膜中KOR和DOR的蛋白水平显著增加。用NOS抑制剂N(ω)-硝基-L-精氨酸甲酯或L-N(6)-(1-亚氨基乙基)-赖氨酸盐酸盐治疗可减少血浆外渗,并抑制慢性肠道炎症期间U50,488H和DPDPE增强的抗渗出作用。数据表明,KOR和DOR激动剂增强的抗渗出作用可能与肠道中KOR和DOR表达增加有关,并且一氧化氮的释放可能在慢性炎症期间增强阿片类药物的作用中发挥作用。